Ryne Biotechnology awarded $4M to advance therapies for Parkinson’s, other CNS disorders
Click Here to Manage Email Alerts
Ryne Biotechnology Inc. has announced a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine to advance its lead candidate for the treatment of Parkinson’s disease.
According to a company press release, RNDP-001 is a dopamine neuron progenitor derived from induced pluripotent stem cells for treatment of both inherited and idiopathic forms of PD. The novel therapeutic has completed preclinical efficacy and safety studies, the company stated, and the research grant will allow Ryne Bio to submit an investigational new drug application to the FDA within the next 12 months.
“We appreciate the California Institute for Regenerative Medicine’s partnership in our vision to reverse degenerative conditions of the brain by developing off-the-shelf cell replacement therapies,” Nick Manusos, CEO of Ryne Bio, stated in the release. “A dramatic shift in the standard of care for patients with neurodegenerative disease is long overdue.”
In addition to RNDP-001, Ryne Bio is developing several other therapeutics, including next-generation, gene-modified programs aimed at reversing disease progression in PD and other disorders of the central nervous system.
“The underlying cause of Parkinson’s disease is progressive degeneration of a patient’s dopamine neurons,” Howard Federoff, MD, PhD, Ryne Bio’s chief medical officer and principal investigator on the award, said in the release. “Ryne Bio is able to directly replace dopamine neurons that have been lost by utilizing precision manufacturing techniques.”